On January 29, 2025, Tyra Biosciences, Inc. announced the appointment of Adele Gulfo to its Board of Directors. Ms. Gulfo brings nearly three decades of executive leadership experience to the TYRA board.
Ms. Gulfo has a strong track record in developing and commercializing best-selling medicines during her tenure at Pfizer. Her expertise is expected to be valuable as Tyra Biosciences advances its pipeline of precision medicines.
This strategic addition to the board enhances the company's governance and provides critical commercialization insights as its lead programs, such as TYRA-300, progress through clinical development towards potential market entry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.